To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

Amgen AMGN will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...